NovaBay Pharmaceuticals, Inc., a medical device company, develops products for the eye care markets in the United States and internationally. The company offers Avenova, a solution for cleansing and removing foreign materials, including microorganisms and debris from skin around the eye, including the eyelid; CelleRx Clinical Reset, a gentle and soothing facial spray; and NeutroPhase and PhaseOne for the wound care market. It also offers KN95 Masks. The company sells its products through distribution partners, as well as offers Avenova and CelleRx Clinical Reset through online sales channels. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.
IPO Year: 2007
Exchange: AMEX
Website: novabay.com
| Date | Price Target | Rating | Analyst |
|---|
NEW YORK, Dec. 9, 2020 /PRNewswire/ -- The current pandemic has been devastating for the global economy and has caused severe backlogs in hospitals. Additionally, a spike in demand for Personal Protective Equipment (PPE) and new disinfecting technologies has also been seen. For example, when it comes for PPE, the global market was valued at USD 52.7 Billion in 2019 and is expected to reach USD 92.5 Billion by 2025 while growing at a CAGR of 8.7% during 2020-2025, according to VynZ Research. As for new technologies for disinfection, a recent example comes from LG Electronics, which announced on Wednesday the launch of a disinfection robot that will assist in containing the spread of the vi
8-K - NovaBay Pharmaceuticals, Inc. (0001389545) (Filer)
10-K - NovaBay Pharmaceuticals, Inc. (0001389545) (Filer)
NT 10-K - NovaBay Pharmaceuticals, Inc. (0001389545) (Filer)
DEF 14A - NovaBay Pharmaceuticals, Inc. (0001389545) (Filer)
8-K - NovaBay Pharmaceuticals, Inc. (0001389545) (Filer)
DEFA14A - NovaBay Pharmaceuticals, Inc. (0001389545) (Filer)
8-K - NovaBay Pharmaceuticals, Inc. (0001389545) (Filer)
PRE 14A - NovaBay Pharmaceuticals, Inc. (0001389545) (Filer)
DEFA14A - NovaBay Pharmaceuticals, Inc. (0001389545) (Filer)
8-K - NovaBay Pharmaceuticals, Inc. (0001389545) (Filer)
4 - NovaBay Pharmaceuticals, Inc. (0001389545) (Issuer)
4 - NovaBay Pharmaceuticals, Inc. (0001389545) (Issuer)
4 - NovaBay Pharmaceuticals, Inc. (0001389545) (Issuer)
4 - NovaBay Pharmaceuticals, Inc. (0001389545) (Issuer)
4 - NovaBay Pharmaceuticals, Inc. (0001389545) (Issuer)
4 - NovaBay Pharmaceuticals, Inc. (0001389545) (Issuer)
4 - NovaBay Pharmaceuticals, Inc. (0001389545) (Issuer)
Stockholders as of the March 18, 2025 record date will be entitled to vote Company engages financial advisor to explore strategic options should stockholders fail to approve the dissolution proposal NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) ("NovaBay" or the "Company") announces it will hold a virtual Special Meeting on April 16, 2025, at which stockholders will vote on a proposal for the liquidation and dissolution of the Company under Delaware law, pursuant to the Plan of Complete Liquidation and Dissolution of the Company (the "Dissolution"). The Special Meeting was announced in a preliminary proxy statement on Schedule 14A filed with the Securities and Exchange Commission ("SEC") on F
Stockholders voted to unlock the value of NovaBay's Avenova® eyecare business by approving the $11.5 million asset sale Reconvened Special Meeting adjourned to allow additional time for votes to reach the 50% threshold of outstanding common stock in favor of Proposal Two, providing for the Dissolution of the Company Stockholders who have not yet voted are strongly encouraged to vote FOR Proposal Two at the Special Meeting scheduled to reconvene on January 30, 2025 NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) ("NovaBay" or the "Company") announces the completion of the sale of its Avenova eyecare business and related assets to PRN Physician Recommended Nutriceuticals, LLC ("PRN") for $11.
Reconvened meeting adjourned due to insufficient votes to reach the 50% threshold of outstanding common shares voting in favor of Proposal One and Proposal Two Stockholders who have not voted are strongly encouraged to vote FOR Proposal One and FOR Proposal Two at the Special Meeting to reconvene on January 16, 2025 NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) ("NovaBay" or the "Company") announces that its Reconvened Special Meeting of Stockholders held on December 18, 2024 has been adjourned until January 16, 2025 at 11:00 a.m. Pacific time to provide stockholders additional time to vote on Proposal One and Proposal Two. Both proposals received significant support based on the shares tha
Stockholders are urged to vote FOR Proposal One and Proposal Two before the reconvened Special Meeting scheduled for December 18 NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) ("NovaBay" or the "Company") announces that Chief Executive Officer Justin Hall has issued the following Letter to Stockholders: To My Fellow Stockholders, You have the opportunity to approve a transaction that I fully support and that our Board of Directors unanimously believes is in your best interest. Through the proposed sale of NovaBay's eyecare business and Avenova® brand to PRN Physician Recommended Nutriceuticals, LLC ("PRN"), NovaBay will be able to monetize the value of an asset that has been built over the
Initial meeting adjourned due to insufficient votes to reach the 50% threshold of outstanding common shares voting in favor of Proposal One and Proposal Two Stockholders who have not voted are strongly encouraged to vote FOR Proposal One and Proposal Two NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) ("NovaBay" or the "Company") announces that its Special Meeting of Stockholders held on November 22, 2024 has been adjourned until December 18, 2024 at 11:00 a.m. Pacific time to provide stockholders additional time to vote on Proposal One and Proposal Two. Both proposals received significant support based on the shares that have been voted by stockholders but have yet to reach the 50% threshold
NovaBay urges stockholders to vote FOR all proxy proposals at the Special Meeting of Stockholders NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) ("NovaBay" or the "Company") announces that the largest institutional advisory firm, Institutional Shareholder Services (ISS), has recommended that NovaBay stockholders vote in favor of all of the Company's proxy proposals, specifically to authorize and approve the sale of its eyecare business (the "Asset Sale Proposal") and approve the voluntary liquidation and dissolution of the Company (the "Dissolution Proposal"). Proposal One (the Asset Sale Proposal) and Proposal Two (the Dissolution Proposal) are further described in the Definitive Proxy Statem
Online Avenova® sales increase 14% for the quarter and 19% for the nine months Sales and marketing expenses declined 25% for the quarter and 18% for the nine months reflecting digital marketing optimization NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) reports financial results for the three and nine months ended September 30, 2024. "Avenova sales through the online channel for the quarter increased 14% over the prior year, while we reduced our marketing spend by 25% in the same period as we further optimized our highly efficient digital marketing programs," said Justin Hall, CEO of NovaBay. "We saw continued momentum in Avenova online sales into the current quarter. Sales through Amazon
NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) ("NovaBay" or the "Company") today announces that the Company has accepted a revised transaction proposal from PRN Physician Recommended Nutriceuticals, LLC ("PRN") to increase the base purchase price for the Company's eyecare business from $9.5 million to $11.5 million. The Company has entered into an amendment (the "Amendment") to its previously announced Asset Purchase Agreement, dated September 19, 2024, with PRN (the "Original PRN APA" and, as amended, the "PRN APA"). The Company's transaction with PRN remains subject to certain closing conditions, including receiving stockholder approval. "We are pleased to accept PRN's revised offer for the
NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) ("NovaBay" or the "Company") announces that the Company's board of directors has determined that an unsolicited and non-binding offer from Refresh Acquisitions BidCo LLC ("Refresh") for an affiliate of Refresh to acquire the Company's Avenova® brand and related assets is a "Superior Proposal" to the Company's asset purchase agreement with PRN Physician Recommended Nutriceuticals, LLC ("PRN"). Refresh's unsolicited offer provides for terms that are substantially similar to the contemplated transaction with PRN, except that the Company would receive a purchase price of up to $11.5 million (compared with $9.5 million in the transaction with PRN), subj
This Acquisition Enhances PRN Physician Recommended Nutriceuticals' ("PRN") Product Portfolio of Science-Based Eye Health Products BLUE BELL, Pa., Sept. 20, 2024 /PRNewswire/ -- Acumen Health Holdings, LLC, a professionally recommended, consumer-preferred dietary supplements company focused on eye health and companion animals, announced today that its subsidiary, PRN Physician Recommended Nutriceuticals, LLC, has entered into a definitive asset purchase agreement to acquire the assets of the Avenova® brand (the "Brand") and business from NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) ("NovaBay"). The Brand offers several products for ocular health including cleansing sprays, absorbent wipes, and
SC 13G/A - NovaBay Pharmaceuticals, Inc. (0001389545) (Subject)
SC 13G/A - NovaBay Pharmaceuticals, Inc. (0001389545) (Subject)
SC 13G/A - NovaBay Pharmaceuticals, Inc. (0001389545) (Subject)
SC 13G/A - NovaBay Pharmaceuticals, Inc. (0001389545) (Subject)
SC 13G - NovaBay Pharmaceuticals, Inc. (0001389545) (Subject)
SC 13G/A - NovaBay Pharmaceuticals, Inc. (0001389545) (Subject)
SC 13G - NovaBay Pharmaceuticals, Inc. (0001389545) (Subject)
4 - NovaBay Pharmaceuticals, Inc. (0001389545) (Issuer)
4 - NovaBay Pharmaceuticals, Inc. (0001389545) (Issuer)
4 - NovaBay Pharmaceuticals, Inc. (0001389545) (Issuer)
4 - NovaBay Pharmaceuticals, Inc. (0001389545) (Issuer)
4 - NovaBay Pharmaceuticals, Inc. (0001389545) (Issuer)
4 - NovaBay Pharmaceuticals, Inc. (0001389545) (Issuer)
4 - NovaBay Pharmaceuticals, Inc. (0001389545) (Issuer)
3 - NovaBay Pharmaceuticals, Inc. (0001389545) (Issuer)
4 - NovaBay Pharmaceuticals, Inc. (0001389545) (Issuer)
4 - NovaBay Pharmaceuticals, Inc. (0001389545) (Issuer)
NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) announces that it will report financial results for the three and six months ended June 30, 2024 after market close on Tuesday, August 13, 2024 and will hold an investment community conference call that day beginning at 4:30 p.m. Eastern time. Date/Time: Tuesday, August 13, 4:30 p.m. ET / 1:30 p.m. PT Pre-Registration: Participants can pre-register for the conference call here: Callers who pre-register will be emailed conference details and unique Registration ID to gain immediate access to the call and bypass the live operator. Participants may pre-register at any time, including up to and
Net product sales increased 13% over the prior year driven by higher sales of Avenova®-branded products through OTC channels and branded wound care products Sales and marketing expenses declined 15% reflecting continued digital marketing optimization Ordered product sales for Avenova-branded products on Amazon.com reached new all-time records in March and April Conference call begins at 4:30 p.m. Eastern time today NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) reports financial results for the three months ended March 31, 2024 and provides a business update. "Net product sales growth of 13% versus the prior year was driven by higher sales of Avenova-branded products through online
NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) announces that it will report financial results for the three months ended March 31, 2024 after market close on Thursday, May 9, 2024 and will hold an investment community conference call that day beginning at 4:30 p.m. Eastern time. Date/Time: Thursday, May 9, 4:30 p.m. ET / 1:30 p.m. PT Pre-Registration: Participants can pre-register for the conference call here: Callers who pre-register will be emailed conference details and unique Registration ID to gain immediate access to the call and bypass the live operator. Participants may pre-register at any time, including up to and after the call start time.
Q4 net sales from the eyecare and wound care segment grew 10% over the prior year with higher sales from the Avenova® physician dispensed and OTC channels, and from branded wound care products Sales and marketing expenses for the quarter declined 27% reflecting digital marketing optimization Divestiture of skincare segment expected to bolster cash position and reduce operating expenses Continued execution on eyecare growth strategy including recent co-marketing partnership Conference call begins at 4:30 p.m. Eastern time today NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) reports financial results for the three and 12 months ended December 31, 2023 and provides a business update.
NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) announces that it will report financial results for the three and 12 months ended December 31, 2023 after market close on Tuesday, March 26, 2024 and will hold an investment community conference call that day beginning at 4:30 p.m. Eastern time. Date/Time: Tuesday, March 26, 4:30 p.m. ET / 1:30 p.m. PT Pre-Registration: Participants can pre-register for the conference call here: Callers who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator. Participants may pre-register at any time, inc
DERMAdoctor sale reduces operating expenses and bolsters cash NovaBay® Pharmaceuticals, Inc. (NYSE:NBY), a company developing and commercializing high-quality eyecare and wound care products, announces that the Company has entered into an agreement to sell its DERMAdoctor® skincare business including all product inventory for approximately $1.0 million in cash. NovaBay expects to close the transaction before the end of the first quarter of 2024 and provide certain transitional services for the next 90 days. "This sale will reduce our quarterly operating expenses and provide us with much-needed cash during this challenging capital market environment. It also streamlines our business by p
Net product revenue from Avenova®-branded eyecare products grew 7% year-over-year, reflecting an increased contribution from the physician dispensed channel Sales and marketing expenses declined 7% versus the prior year through continued optimized digital marketing programs Operating loss for the first nine months of 2023 narrowed by 16% from the prior year Marketing activities are underway to promote differentiated, high-quality Avenova Allograft to a broad target audience of U.S. eyecare specialists Conference call begins at 4:30 p.m. Eastern time today NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) reports financial results for the three and nine months ended September 30, 2023
NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) announces that it will report financial results for the three and nine months ended September 30, 2023 after market close on Thursday, November 9, 2023 and will hold an investment community conference call that day beginning at 4:30 p.m. Eastern time. Date/Time: Thursday, November 9, 4:30 p.m. ET / 1:30 p.m. PT Pre-Registration: Participants can pre-register for the conference call here: Callers who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator. Participants may pre-register at any time, incl
Net product revenue of $4.6 million increased 26% over the prior-year quarter Wound care sales of $1.3 million mark a record quarterly high Sales and marketing expenses reduced by 16% through optimized digital marketing programs Operating loss decreased by 37% year-over-year Conference call begins at 4:30 p.m. Eastern time today NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) reports financial results for the three and six months ended June 30, 2023 and provides a business update. "Net product revenue reached $4.6 million for the quarter, up 26% from the prior year as we benefited from a particularly strong quarter in our wound care segment," said Justin Hall, NovaBay CEO. "We co
NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) announces that it will report financial results for the three and six months ended June 30, 2023 after market close on Thursday, August 10, 2023 and will hold an investment community conference call that day beginning at 4:30 p.m. Eastern time. Date/Time: Thursday, August 10, 4:30 p.m. ET / 1:30 p.m. PT Pre-Registration: Participants can pre-register for the conference call here: Callers who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator. Participants may pre-register at any time, in